Literature DB >> 15619642

Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.

Dan Wu1, Yuhuan Qiao, Gunnar B Kristensen, Shanshan Li, Gunhild Troen, Ruth Holm, Jahn M Nesland, Zhenhe Suo.   

Abstract

The protein and mRNA expression of dysadherin was studied in a series of squamous cell cervical carcinomas, and their clinicopathological associations and prognostic value were explored. Immunohistochemistry was used to assess protein expression of dysadherin in 206 patients with squamous cell cervical carcinoma, FIGO stage Ia-IVb. Frozen tissues from 20 cases in which the tumors showed variable dysadherin protein expression were used for laser capture microdissection (LCM) and processed for RTPCR detection of dysadherin mRNA. Immunohistochemically, all the dysadherin-positive staining was membranous. Positive cell membranous dysadherinpositive staining was often observed at the edge of tumor nests, although strong immunoreactivity throughout whole tumor nests was also seen in some tumors. Basal cells of the normal cervical epithelia were positive for dysadherin while its expression in the squamous cell cervical carcinomas was variable. Among the 206 tumors, 23 (11.2%) were negative, 53 (25.7%) were scored 1+, 54 (26.2%) were scored 2+ and 76 (36.9%) were scored 3+. In the 20 tumors analyzed, mRNA expression of dysadherin basically corresponded to its protein expression. No significant correlation between expression of dysadherin and age, FIGO stage or lymph node status was observed. Higher level of dysadherin expression, however, was significantly associated with shorter overall survival (p=0.04). We conclude that there is dysadherin protein expression in basal and parabasal cells of normal cervical epithelia, and higher level of dysadherin protein expression in squamous cell cervical carcinoma is predictive of a shorter overall survival, indicating that dysadherin may be a valuable prognostic marker in cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619642     DOI: 10.1007/BF03033763

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  18 in total

1.  Prognostic factors related to cervical cancer survival in Mexican women.

Authors:  L Flores-Luna; E Salazar-Martinez; P Escudero-De los Rios; G Gonzalez-Lira; S Zamora-Muñoz; E Lazcano-Ponce
Journal:  Int J Gynaecol Obstet       Date:  2001-10       Impact factor: 3.561

2.  Clinical significance of tumor size in stage IB and II carcinoma of the uterine cervix.

Authors:  T. Kawagoe; M. Kashimura; Y. Matsuura; K. Sugihara; N. Toki; T. Aoki
Journal:  Int J Gynecol Cancer       Date:  1999-09       Impact factor: 3.437

3.  Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.

Authors:  Hitomi Tsuiji; Seiichi Takasaki; Michiie Sakamoto; Tatsuro Irimura; Setsuo Hirohashi
Journal:  Glycobiology       Date:  2003-04-02       Impact factor: 4.313

4.  E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma.

Authors:  E Carico; M Atlante; B Bucci; I Nofroni; A Vecchione
Journal:  Gynecol Oncol       Date:  2001-02       Impact factor: 5.482

5.  Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression.

Authors:  Takeshi Shimamura; Michiie Sakamoto; Yoshinori Ino; Yasuto Sato; Kazuaki Shimada; Tomoo Kosuge; Hisahiko Sekihara; Setsuo Hirohashi
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

6.  Dysadherin: expression and clinical significance in thyroid carcinoma.

Authors:  Haruhiro Sato; Yoshinori Ino; Ayaka Miura; Yoshifumi Abe; Hideto Sakai; Koichi Ito; Setsuo Hirohashi
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

7.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.

Authors:  K F Becker; M J Atkinson; U Reich; I Becker; H Nekarda; J R Siewert; H Höfler
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

8.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

9.  Quantitative analysis of cadherin-catenin-actin reorganization during development of cell-cell adhesion.

Authors:  C L Adams; W J Nelson; S J Smith
Journal:  J Cell Biol       Date:  1996-12       Impact factor: 10.539

10.  Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts.

Authors:  N Matsuyoshi; M Hamaguchi; S Taniguchi; A Nagafuchi; S Tsukita; M Takeichi
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  10 in total

1.  Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma.

Authors:  Anna Batistatou; Alexander K Charalabopoulos; Chrisoula D Scopa; Yukihiro Nakanishi; Angelos Kappas; Setsuo Hirohashi; Niki J Agnantis; Konstantinos Charalabopoulos
Journal:  Virchows Arch       Date:  2006-03-29       Impact factor: 4.064

2.  A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody.

Authors:  Catharina Steentoft; Max Fuhrmann; Federico Battisti; Julie Van Coillie; Thomas D Madsen; Diana Campos; Adnan Halim; Sergey Y Vakhrushev; Hiren J Joshi; Hans Schreiber; Ulla Mandel; Yoshiki Narimatsu
Journal:  Glycobiology       Date:  2019-04-01       Impact factor: 4.313

3.  Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.

Authors:  Anna Batistatou; Konstantinos Charalabopoulos; Yukihiro Nakanishi; Constantine Vagianos; Setsuo Hirohashi; Niki J Agnantis; Chrissoula D Scopa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 4.  Dysadherin: a new player in cancer progression.

Authors:  Jeong-Seok Nam; Setsuo Hirohashi; Lalage M Wakefield
Journal:  Cancer Lett       Date:  2007-04-17       Impact factor: 8.679

5.  MMP8 increases tongue carcinoma cell-cell adhesion and diminishes migration via cleavage of anti-adhesive FXYD5.

Authors:  K Juurikka; A Dufour; K Pehkonen; B Mainoli; P Campioni Rodrigues; N Solis; T Klein; P Nyberg; C M Overall; T Salo; P Åström
Journal:  Oncogenesis       Date:  2021-05-31       Impact factor: 7.485

6.  Involvement of dysadherin and E-cadherin in the development of testicular tumours.

Authors:  A Batistatou; C D Scopa; P Ravazoula; Y Nakanishi; D Peschos; N J Agnantis; S Hirohashi; K A Charalabopoulos
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

7.  In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.

Authors:  A Batistatou; D Peschos; H Tsanou; A Charalabopoulos; Y Nakanishi; S Hirohashi; N J Agnantis; K Charalabopoulos
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

8.  Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.

Authors:  Samuel Jang; Xiao-Min Yu; Celina Montemayor-Garcia; Kamal Ahmed; Eric Weinlander; Ricardo V Lloyd; Ajitha Dammalapati; David Marshall; James R Prudent; Herbert Chen
Journal:  Oncotarget       Date:  2017-04-11

9.  Prognostic value of dysadherin in cancer: A systematic review and meta-analysis.

Authors:  Aino Niinivirta; Tuula Salo; Pirjo Åström; Krista Juurikka; Maija Risteli
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

10.  FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas.

Authors:  Pichai Raman; Timothy Purwin; Richard Pestell; Aydin Tozeren
Journal:  Cancer Inform       Date:  2015-10-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.